General Anesthesia Market Forecasts to 2030 – Global Analysis By Type of Drugs (Propofol, Desflurane, Sevoflurane, Thiopental and Other Type of Drugs), Route of Administration (Inhalation and Intravenous), Application, End User and By Geography.

General Anesthesia Market Forecasts to 2030 – Global Analysis By Type of Drugs (Propofol, Desflurane, Sevoflurane, Thiopental and Other Type of Drugs), Route of Administration (Inhalation and Intravenous), Application, End User and By Geography.

According to Stratistics MRC, the Global General Anaesthesia Market is accounted for $6.01 billion in 2023 and is expected to reach $8.74 billion by 2030 growing at a CAGR of 6.2% during the forecast period. General anaesthesia is a medical state induced in a patient to ensure unconsciousness, analgesia, muscle relaxation, and amnesia during a medical procedure or surgery. It allows for extended surgeries, benefits paediatric and geriatric patients, and facilitates critical care and diagnostic tests.

According to the Interactive cardiovascular and thoracic surgery, in April 2022, it was reported that around 227,442 populations above 70 years undergo cardiovascular procedure.

Market Dynamics:

Driver:

Increasing surgical procedures

The increasing number of surgical procedures is a significant driver of the general anaesthesia market. As the global population grows and ages, there is a rising demand for surgical interventions to address various medical conditions, from routine surgeries to complex, life-saving procedures. General anaesthesia is essential in ensuring patient comfort and safety during these surgeries, as it induces a controlled state of unconsciousness and analgesia. Furthermore, advancements in surgical techniques and the expansion of healthcare infrastructure in developing countries contribute to the growing number of surgeries. This increased demand for general anaesthesia services and products is expected to continue driving market growth in the healthcare industry.

Restraint:

Cost of equipment and drugs

Anaesthesia requires specialised equipment and pharmaceuticals, both of which come at a considerable expense. High initial capital investments for anaesthesia machines, monitors, and medication procurement can strain the financial resources of healthcare facilities. Moreover, the ongoing costs of maintenance, drug supplies, and updates to comply with safety standards can be burdensome. This financial burden can limit the accessibility of anaesthesia services, particularly in resource-constrained healthcare settings, and may discourage some facilities from offering or expanding these services, thus restraining the growth of the general anaesthesia market.

Opportunity:

Demand for minimally invasive surgery

Minimally Invasive Surgery (MIS) represents a significant opportunity for the general anaesthesia market. This surgical approach, which includes procedures like laparoscopy and endoscopy, relies on anaesthesia to ensure patient comfort and immobility during surgery. This surgery is gaining popularity due to its benefits, including smaller incisions, reduced postoperative pain, shorter hospital stays, and quicker recovery times. As the demand for minimally invasive surgery procedures continues to rise, the need for appropriate anaesthesia services and products increases. Anaesthesia plays a crucial role in maintaining patient safety and comfort during these minimally invasive surgeries, making it an integral part of the healthcare system's response to this growing trend. This trend is expected to drive the growth of the general anaesthesia market.

Threat:

Safety concerns

Safety concerns represent a significant threat to the general anaesthesia market. Anaesthesia, while crucial for patient comfort during surgery, carries inherent risks, including allergic reactions, adverse events, and rare complications. High-profile cases of anaesthesia-related incidents can erode public trust and raise concerns among patients. Safety remains a paramount focus for healthcare providers, and any perceived risk can deter patients from opting for surgery or anaesthesia. Additionally, stringent safety standards and regulatory requirements can increase the complexity and cost of providing anaesthesia services.

Covid-19 Impact

The COVID-19 pandemic has exerted a significant impact on the general anaesthesia market. The initial wave of COVID-19 led to the postponement of elective surgeries to conserve resources, prioritise COVID-19 patients, and reduce infection risk. This substantial reduction in surgical volume significantly affected the demand for general anaesthesia services, impacting both anaesthesia providers and the broader healthcare industry. Additionally, supply chain disruptions led to shortages and increased prices for essential anaesthesia drugs and equipment. Despite these challenges, the pandemic prompted the rapid adoption of telemedicine and remote monitoring in anaesthesia care to minimise in-person contact. While the pandemic had a temporary disruptive effect, the need for anaesthesia services remains essential in healthcare, and the market is expected to recover and adapt in the post-pandemic landscape.

The Intravenous segment is expected to be the largest during the forecast period

The Intravenous segment is estimated to hold the largest share. The intravenous segment of the general anaesthesia market refers to the administration of anaesthesia drugs directly into the patient's bloodstream via a vein. This method ensures the rapid onset of anaesthesia, allowing for precise control of the anaesthetic effect. IV anaesthesia is commonly used in various surgical procedures and medical interventions, including the induction and maintenance of general anaesthesia. Furthermore, anaesthesiologists and healthcare providers carefully monitor and adjust the drug dosage throughout the procedure to maintain the patient's unconsciousness, analgesia, and physiological stability. IV anaesthesia is a fundamental and versatile component of general anaesthesia, contributing to patient comfort, safety, and the success of surgical and medical interventions.

The General Surgery segment is expected to have the highest CAGR during the forecast period

The General Surgery segment is anticipated to have lucrative growth during the forecast period. General surgery encompasses a wide range of surgical procedures that don't fall under specialised categories like cardiac or neurological surgeries. General anaesthesia is commonly administered in these surgeries to ensure patient comfort, muscle relaxation, and unconsciousness. It enables surgeons to perform various procedures, such as appendectomy, hernia repairs, gallbladder removal, and many more, with precision. Furthermore, the demand for general anaesthesia in general surgery is significant, as it allows for pain control, immobility, and a controlled surgical environment, playing a vital role in the success of diverse surgical interventions and contributing significantly to the general anaesthesia market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. Factors driving its expansion include a burgeoning population, rising healthcare infrastructure, and increasing access to surgical interventions. The region's ageing population has led to a higher demand for surgical procedures, particularly in countries like China and India. Furthermore, the adoption of advanced healthcare technologies and the increasing awareness of patient safety contribute to the growth of the anaesthesia market. Moreover, government initiatives and foreign investments in healthcare are expected to further bolster the Asia-Pacific general anaesthesia market, making it a pivotal contributor to the global healthcare landscape.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The region is characterised by advanced healthcare infrastructure, high healthcare expenditures, and a strong emphasis on patient safety. Technological advancements, stringent regulatory standards, and a focus on patient comfort and safety drive continuous growth in this market. Additionally, the region is marked by significant research and innovation in anaesthesia techniques, equipment, and pharmaceuticals. The COVID-19 pandemic prompted a renewed emphasis on safety, and North America's healthcare systems have adapted to new challenges, ensuring that the general anaesthesia market in this region remains pivotal in the field of healthcare.

Key players in the market

Some of the key players in the General Anesthesia Market include Baxter International Inc., Pfizer Inc., Fresenius SE & Co. KGaA, Abbott Laboratories, Medtronic plc, AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., GE Healthcare, AstraZeneca plc, Avet Pharmaceuticals Inc, Paion AG, Hikma Pharmaceuticals plc, Aspen Pharmacare Holdings Limited, Claris Lifesciences Limited, Glenmark Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd, Maruishi Pharmaceutical Co. Ltd., Pacira Pharmaceuticals Inc. and Teva Pharmaceutical Industries Limited.

Key Developments:

In April 2022, GE Healthcare, a U.S.-based multinational healthcare and medical technology company, received the U.S. Food and Drugs Approval (FDA) pre-market approval (PMA) for its End-tidal (Et) control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System. The device is to have a direct control of the end-tidal concentration that reflects the drug level in the patient’s blood along with that low-flow anesthesia has benefits for hospitals and the environment.

In February 2022, Sedana Medical AB has launched Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) will be approved by the European DCP In addition, in July 2021. the product has been granted national approval in 14 nations. Additional marketing clearance applications were submitted in the same year, and the business expects to gain national approvals in Italy, Poland, Switzerland, and the United Kingdom in 2022.

In January 2022, Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratoires Théa SAS (Théa). Théa will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic intended for ocular surface anaesthetic during ophthalmologic operations, as a result of the strategic move.

Type of Drugs Covered:
• Propofol
• Desflurane
• Sevoflurane
• Thiopental
• Other Type of Drugs

Route of Administrations Covered:
• Inhalation
• Intravenous

Applications Covered:
• Cardiovascular Surgeries
• Neurosurgeries
• Orthopedic Surgeries
• General Surgery
• Gastrointestinal Procedures
• Other Applications

End Users Covered:
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements